WASHINGTON, Mar 30: Biogen Idec Inc said yesterday it will charge 54,900 dollar a year for its multiple sclerosis drug, Tecfidera, which received US approval on Wednesday. The company has priced the drug at a discount to key competitors such as Novartis AG’s MS pill Gilenya, which costs roughly $60,000 a year, in a bid to maximize its market share. (agencies)
Follow our WhatsApp channel
